Biodexa Pharmaceuticals (BDRX) Total Non-Current Liabilities (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Total Non-Current Liabilities across 13 years of filings, most recently posting $857957.2 for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 53.06% year-over-year to $857957.2; the TTM figure through Dec 2025 stood at $857957.2 (down 53.06% YoY), while the FY2025 annual figure was $850439.2, down 53.28% from the prior year.
• Total Non-Current Liabilities came in at $857957.2 for Q4 2025 at Biodexa Pharmaceuticals, down from $1.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $2.2 million in Q2 2024 to a low of $366139.8 in Q4 2023.
• Average Total Non-Current Liabilities over 5 years is $998114.6, with a median of $846861.9 recorded in 2021.
• Year-over-year, Total Non-Current Liabilities surged 617.48% in 2021 and sank 53.06% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $835766.6 in 2021, then sank by 35.02% to $543065.8 in 2022, then plunged by 32.58% to $366139.8 in 2023, then surged by 399.18% to $1.8 million in 2024, then slumped by 53.06% to $857957.2 in 2025.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $857957.2 in Q4 2025, $1.2 million in Q2 2025, and $1.8 million in Q4 2024.